Ondansetron Tablet, Orally Disintegrating
Product Images NDC 55154-8339

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Ondansetron (NDC 55154-8339). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

8mg Bag Label (B50c1767 8a50 49ab Be31 6533021ae7c4 00)

8mg Bag Label (B50c1767 8a50 49ab Be31 6533021ae7c4 00)
This is a description of Ondansetron Orally Disintegrating Tablets, USP 8 mg. Each tablet contains Ondansetron USP 8 mg and is suitable for phenylketonurics as it contains 3.37 mg phenylalanine per tablet. The usual dosage and administration instructions can be found in the product insert. It is essential to store the tablets at 20° to 25° C (68° to 77° F). The tablets should not be removed from the blister pack until immediately before use. Additionally, when dispensed for outpatient use, the blisters should be provided in a child-resistant container. The packaging is not child-resistant and is intended for institutional use only. Keep out of reach of children and dispense in a tight, light-resistant container. Instructions on how to separate the tablets from the blister pack and administration are provided. The tablets are made in India and distributed by Aurobindo Pharma USA, Inc. and Cardinal Health.*
FDA Label Image

Chemical Structure (Ondansetronod Str)

Chemical Structure (Ondansetronod Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.